Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M204Revenue (TTM) $M63.4Net Margin (%)10.1Altman Z-Score17.3
Enterprise Value $M99.2EPS (TTM) $0.2Operating Margin %11.2Piotroski F-Score6
P/E(ttm)32.2Beneish M-Score-2.6Pre-tax Margin (%)13.4Higher ROA y-yY
Price/Book1.910-y EBITDA Growth Rate %--Quick Ratio13.7Cash flow > EarningsN
Price/Sales3.25-y EBITDA Growth Rate %--Current Ratio15.1Lower Leverage y-yY
Price/Free Cash Flow33.5y-y EBITDA Growth Rate %1,446ROA % (ttm)5.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)6.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M14.4ROIC % (ttm)32.7Gross Margin Increase y-yY

Gurus Latest Trades with GENC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GENCMario Gabelli 2016-09-30 Buy $9.89 - $12.8
($11.42)
$ 15.4535%New holding13,800
GENCKeeley Asset Management Corp 2010-03-31 Sold Out $4.6 - $5.2
($4.88)
$ 15.45217%Sold Out0
GENCKeeley Asset Management Corp 2009-09-30 Buy $4.25 - $5.73
($4.84)
$ 15.45219%New holding45,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GENC is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GENC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Maingot LawrenceVice President and Controller 2016-12-07Sell2,500$15.65-1.28view
Houtkin Sherry10% Owner 2016-12-06Sell18,727$15.55-0.64view
Houtkin Sherry10% Owner 2016-12-02Sell25,000$15.64-1.21view
Houtkin Sherry10% Owner 2016-12-02Sell25,000$15.64-1.21view
Houtkin Sherry10% Owner 2016-12-01Sell5,000$14.179.03view
Houtkin Sherry10% Owner 2016-11-29Sell814$14.228.65view
Houtkin Sherry10% Owner 2016-11-23Sell3,101$14.814.32view
Houtkin Sherry10% Owner 2016-11-22Sell10,000$14.933.48view
Houtkin Sherry10% Owner 2016-11-18Sell2,390$14.794.46view
Maingot LawrenceVice President and Controller 2016-08-29Sell1,500$1228.75view

Quarterly/Annual Reports about GENC:

News about GENC:

Articles On GuruFocus.com
A Value Stock to Profit From Trump's Presidency Nov 11 2016 
Mario Gabelli Gives Stock Recommendations Feb 26 2016 
Winning with the Net Current Asset Value Approach to Stocks Sep 04 2013 
Ben Graham Net-Net Newsletter: TSR (TSRI) One Year Later Apr 09 2012 
“Assign Yourself the Right Story” Mar 05 2012 
Ben Graham Net-Net Newsletter: Gencor (GENC) One Year Later Feb 29 2012 
How Long Should You Hold a Net-Net? Feb 13 2012 
Opt-Sciences $OPST- Follow Up Feb 01 2012 
Four Stocks to Fit in a Basket of Negative Enterprise Value with Certain Profitability Dec 23 2011 
Gencor ($GENC)- A free business with a huge portfolio Dec 22 2011 

More From Other Websites
ETFs with exposure to Gencor Industries, Inc. : December 8, 2016 Dec 08 2016
Gencor Industries, Inc. :GENC-US: Earnings Analysis: 2016 By the Numbers : December 7, 2016 Dec 07 2016
Is Autobytel Inc. (ABTL) Going to Burn These Hedge Funds? Dec 05 2016
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 02 2016
Gencor posts 4Q profit Dec 02 2016
Gencor posts 4Q profit Dec 02 2016
Gencor Releases Fourth Quarter and Fiscal Year 2016 Results Dec 02 2016
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) for Relapsed Multiple Myeloma and... Nov 21 2016
A Value Stock to Profit From Trump's Presidency Nov 11 2016
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their... Nov 11 2016
Articles of Association for Genmab A/S Nov 10 2016
CHMP Issues Positive Opinion Recommending Arzerra® (ofatumumab) in Combination with Fludarabine and... Nov 10 2016
Genmab Announces Phase III Study of Daratumumab in Combination with Carfilzomib in Multiple Myeloma Nov 10 2016
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their... Nov 09 2016
Capital Increase in Genmab as a Result of Employee Warrant Exercise Nov 09 2016
Genmab Announces Financial Results for the First Nine Months of 2016 and Improves 2016 Financial... Nov 02 2016
GENCOR RELEASES SECOND QUARTER FISCAL 2016 RESULTS Oct 26 2016
GENCOR RELEASES THIRD QUARTER FISCAL 2016 RESULTS Oct 26 2016
Articles of Association for Genmab A/S Oct 11 2016
U.S. FDA Grants Priority Review for Daratumumab in Relapsed Multiple Myeloma Oct 07 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)